232 completed, 48 recruiting, 48 terminated, 42 unknown. 427 Phase 3, 60 Phase 2.
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup]) [68Ga]-LNTH-2401 - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Lantheus Medical Imaging | 408 | 2026-09-30 | 2026-09-21 |
| RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial Stereotactic body radiotherapy (SBRT) to the prostate bed, Standard-of-care radiotherapy (SOC) to the prostate bed - Prostate Cancer (Post Prostatectomy), Prostate Cancer | Phase 3 | Not yet recruiting | Robert Förster | 206 | 2026-09-01 | 2026-09-21 |
| Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer Experimental - BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 330 | 2026-09-01 | 2026-05-15 |
| Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) 177Lu-NYM032 injection, Best supportive/best standard of care - Prostate Cancer | Phase 3 | Not yet recruiting | Norroy Bioscience Co., LTD | 600 | 2026-08-31 | 2026-08-31 |
| This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer. 68-Ga-NYM032 - Prostate Cancer | Phase 3 | Recruiting | Norroy Bioscience Co., LTD | 232 | 2026-08-31 | 2026-09-15 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-10-16 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| QLC5508 in Participants With Metastatic Prostate Cancer QLC5508, Docetaxel - Prostate Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 700 | 2026-06-20 | 2026-06-08 |
| Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer NanoKnife System, Stereotactic Body Radiation Therapy - Prostate Cancer | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 224 | 2026-04-16 | 2026-09-18 |
| PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost - Prostate Cancer, Brachytherapy | Phase 2 / Phase 3 | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 600 | 2026-03-19 | 2026-07-21 |
| Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Moderate hypofractionated radiotherapy (Moderate-hypoRT), Ultra-hypofractionated radiotherapy (Ultra-hypoRT) - Prostate Cancer | Phase 3 | Recruiting | Samsung Medical Center | 270 | 2026-03-06 | 2026-03-30 |
| Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) multimodal analgesia pathway with up-front small opioid prescription, multimodal analgesia pathway without up-front small opioid prescription, pre-implementation baseline including opioid - Opioid Consumption, Postoperative, Multimodal Analgesia | Phase 3 | Recruiting | Brigham and Women's Hospital | 300 | 2026-03-01 | 2026-05-22 |
| A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer [177-Lu]Ludotadipep, Best supportive care/standard of care (BSC/SOC) alone - Prostate Cancer, mCRPC | Phase 3 | Recruiting | FutureChem | 114 | 2026-01-26 | 2026-10-01 |
| Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment Neurovascular sparing stereotactic body radiation therapy - Prostate Cancer | Phase 3 | Recruiting | Jonsson Comprehensive Cancer Center | 200 | 2025-12-16 | 2025-12-19 |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. Mevrometostat, Placebo, Enzalutamide - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer | Phase 3 | Recruiting | Pfizer | 1000 | 2025-09-28 | 2026-10-14 |
| PSMA PET Combined With MRI for the Detection of PCa 68Ga-PSMA-11 - PCA, Prostate Cancer | Phase 3 | Active not recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 338 | 2025-08-18 | 2026-10-20 |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 700 | 2025-08-06 | 2026-10-14 |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC AAA817, ARPI, Standard of Care - Prostate Cancer | Phase 3 | Recruiting | Novartis Pharmaceuticals | 940 | 2025-07-01 | 2026-10-15 |
| Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer FP-014 - Prostate Cancer | Phase 3 | Withdrawn | Foresee Pharmaceuticals Co., Ltd. | 2025-07-01 | 2025-04-27 | |
| Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer Triptorelin Mesylate - Prostate Cancer | Phase 3 | Withdrawn | Foresee Pharmaceuticals Co., Ltd. | 2025-06-01 | 2025-04-27 |
Showing 20 of 427. Sign in to see all of them.
Prostatic Neoplasms (427) · Neoplasms (27) · Neoplasm Metastasis (21) · Breast Neoplasms (13) · Lung Neoplasms (10) · Pain (9) · Osteoporosis (8) · Erectile Dysfunction (7) · Colorectal Neoplasms (6) · Disease (6) · Colonic Neoplasms (5) · Ovarian Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Hot Flashes (4) · Rectal Neoplasms (4)
Genital Diseases (426) · Urogenital Diseases (426) · Genital Diseases, Male (425) · Genital Neoplasms, Male (424) · Male Urogenital Diseases (424) · Neoplasms by Site (424) · Prostatic Diseases (424) · Urogenital Neoplasms (424) · Neoplasms (400) · Pathological Conditions, Signs and Symptoms (50) · Pathologic Processes (34) · Neoplastic Processes (21) · Signs and Symptoms (20) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16)
Goserelin (46) · Leuprolide (44) · Radiotherapy (43) · bicalutamide (40) · Prednisone (34) · Docetaxel (33) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (29) · Flutamide (23) · Androgen Antagonists (22) · Triptorelin Pamoate (20) · Gonadotropin-Releasing Hormone (17) · enzalutamide (14) · Zoledronic Acid (13) · Radiosurgery (9) · apalutamide (9)
Ferring Pharmaceuticals (21) · Radiation Therapy Oncology Group (20) · European Organisation for Research and Treatment of Cancer - EORTC (11) · Alliance for Clinical Trials in Oncology (10) · UNICANCER (10) · Memorial Sloan Kettering Cancer Center (8) · AstraZeneca (7) · Novartis Pharmaceuticals (7) · Pfizer (7) · SWOG Cancer Research Network (7) · M.D. Anderson Cancer Center (6) · Sir Mortimer B. Davis - Jewish General Hospital (6) · Ipsen (5) · NCIC Clinical Trials Group (5) · Abbott (4)
United States (207) · Canada (115) · France (78) · United Kingdom (70) · Netherlands (57) · Germany (53) · Belgium (52) · Italy (48) · Spain (47) · Australia (44) · Poland (38) · China (36) · Czechia (31) · Sweden (31) · Finland (28)
Michel Bolla, MD (5) · Eric J. Small, MD (4) · Kent E Wallner, MD (4) · Silke Gillessen, Prof (4) · Thomas Hope, MD (4) · Carlos Vargas, MD (3) · George Wilding, MD (3)
PMID 34350976, PMID 38320143, PMID 25592642, PMID 33270906, PMID 36884035, PMID 24722180, PMID 29272162, PMID 36596347, PMID 38421252, PMID 21917607, PMID 22747660, PMID 23228299, PMID 24423462, PMID 24957547, PMID 25712310, PMID 26031410, PMID 29500065, PMID 32994091, PMID 33740734, PMID 33999161, PMID 35643841, PMID 35731340, PMID 35812443, PMID 37751207, PMID 37973477, PMID 38421243, PMID 40539499, PMID 41880608, PMID 10604271, PMID 10717606, PMID 10866876, PMID 10869758, PMID 11289126, PMID 11448906, PMID 11828353, PMID 11895205, PMID 12126818, PMID 12160582, PMID 12177096, PMID 12208577, PMID 12560440, PMID 12743142, PMID 12947070, PMID 14572748, PMID 14581419, PMID 14630265, PMID 14747052, PMID 15020604, PMID 15169799, PMID 15251156
2008 (7), 2017 (4), U10CA031946 (4), 2009 (3), 2023 (3), P30CA016672 (3), U10CA032102 (3), 2005 (2), 2015 (2), 2018 (2), 2019 (2), U10CA037429 (2), 2004 (1), 2014 (1), 2016 (1)